ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 157

Identifying Additional Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Unique Cohort of Antiphospholipid Antibody Positive Chinese Patients

Yu Zuo1, Chun Li2, Song Zhang3, Una Makris1, David Karp4 and Zhan-Guo Li5, 1University of Texas Southwestern Medical Center, Dallas, TX, 2Peking University People's Hospital, Beijing, China, 3University of Texas Southwestern Medical Center, dallas, TX, 4Rheumatology, UT Southwestern Med Ctr, Dallas, TX, 5Rheum/Immunology, Peking University People's Hospital, Beijing, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Antiphospholipid antibodies, antiphospholipid syndrome, pregnancy and thrombosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Antiphospholipid Syndrome Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Risk stratification of asymptomatic aPL carriers is difficult. Our objective was to identify additional clinical and epidemiological predictors of arterial thrombosis, venous thrombosis, and pregnancy morbidities in a large cohort of Chinese aPL carriers.

Methods: This cohort included 297 consecutive persistent aPL positive patients who attended the rheumatology clinic at Peking University People’s Hospital. Among those, 85 had arterial thrombosis, 76 had venous thrombosis, and 34 experienced APS related pregnancy morbidities. 143 patients had at least one persistent positive aPL without any other criteria APS manifestations and were defined as aPL positive control patients. When assessing risk factors associated with pregnancy morbidities, only reproductive age (age<45) female controls were used. Pearson Chi-squared analysis and multivariable logistic regression were used to evaluate correlation between different risk factors and clinical manifestations.

Results: When comparing to asymptomatic aPL positive controls, additional risk factors associated with arterial thrombosis included: hypertension (OR=2.368, 95% CI 1.249 – 4.491, P=0.0083), smoking (OR=6.137, 95% CI 2.408 – 15.637, P=0.0001), and the presence of underlying autoimmune disease (OR=4.401, 95% CI 2.387- 8.113, P<0.0001). Additional risks associated with venous thrombosis included: smoking (OR=4.594, 95%CI 1.681 – 12.553, P=0.029) and the presence of underlying autoimmune disease (OR=6.33, 95%CI 3.355 – 11.94, P<0.0001). The presence of underlying autoimmune disease (OR= 3.301, 95%CI 1.407 – 7.744, P=0.0061) is the only additional risk which demonstrated a significant association with pregnancy morbidity. A high frequency of thrombocytopenia and hypocomplementemia were observed in all +aPLs patients.

Conclusion: Hypertension is a potential predictor for arterial thrombosis. Smoking and the presence of underlying autoimmune disease are potential predictors for both arterial and venous thrombosis among aPL carriers. The presence of underlying autoimmune disease is an additional risk for APS related pregnancy morbidities in +aPL Chinese patients. This is the largest cross sectional comparison between Chinese APS patients and asymptomatic aPL carriers where we are able to identify additional risk factors for thromboembolic events and pregnancy morbidities. Our data may help physicians to risk stratify aPLs positive Asian patients.


Disclosure: Y. Zuo, None; C. Li, None; S. Zhang, None; U. Makris, None; D. Karp, None; Z. G. Li, None.

To cite this abstract in AMA style:

Zuo Y, Li C, Zhang S, Makris U, Karp D, Li ZG. Identifying Additional Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Unique Cohort of Antiphospholipid Antibody Positive Chinese Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/identifying-additional-risk-factors-associated-with-thrombosis-and-pregnancy-morbidity-in-a-unique-cohort-of-antiphospholipid-antibody-positive-chinese-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-additional-risk-factors-associated-with-thrombosis-and-pregnancy-morbidity-in-a-unique-cohort-of-antiphospholipid-antibody-positive-chinese-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology